Russell Investments Group Ltd. Has $133.92 Million Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Russell Investments Group Ltd. boosted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 6.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 252,216 shares of the medical research company’s stock after acquiring an additional 14,582 shares during the quarter. Russell Investments Group Ltd.’s holdings in Thermo Fisher Scientific were worth $133,918,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Private Wealth Partners LLC increased its stake in shares of Thermo Fisher Scientific by 1.0% in the fourth quarter. Private Wealth Partners LLC now owns 85,131 shares of the medical research company’s stock valued at $45,187,000 after buying an additional 815 shares in the last quarter. Addison Advisors LLC increased its stake in shares of Thermo Fisher Scientific by 26.2% in the fourth quarter. Addison Advisors LLC now owns 231 shares of the medical research company’s stock valued at $123,000 after buying an additional 48 shares in the last quarter. Gilliland Jeter Wealth Management LLC acquired a new stake in shares of Thermo Fisher Scientific in the fourth quarter valued at $261,000. Golden State Equity Partners bought a new position in Thermo Fisher Scientific in the fourth quarter valued at about $346,000. Finally, Sonen Capital LLC boosted its holdings in Thermo Fisher Scientific by 9.0% in the fourth quarter. Sonen Capital LLC now owns 1,963 shares of the medical research company’s stock valued at $1,042,000 after acquiring an additional 162 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Evercore ISI raised their price target on Thermo Fisher Scientific from $575.00 to $610.00 and gave the company an “outperform” rating in a report on Thursday, April 4th. Sanford C. Bernstein restated a “market perform” rating on shares of Thermo Fisher Scientific in a report on Monday, January 8th. Raymond James raised their target price on Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an “outperform” rating in a report on Thursday, February 1st. Barclays raised their target price on Thermo Fisher Scientific from $590.00 to $615.00 and gave the stock an “equal weight” rating in a report on Thursday. Finally, Royal Bank of Canada raised their target price on Thermo Fisher Scientific from $592.00 to $642.00 and gave the stock an “outperform” rating in a report on Thursday, February 1st. Five equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $606.76.

Insider Buying and Selling

In related news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total transaction of $5,979,800.00. Following the transaction, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at approximately $74,039,491.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total transaction of $5,979,800.00. Following the transaction, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at approximately $74,039,491.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Michael A. Boxer sold 14,566 shares of the business’s stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total value of $8,186,092.00. Following the completion of the sale, the senior vice president now owns 12,901 shares of the company’s stock, valued at $7,250,362. The disclosure for this sale can be found here. In the last three months, insiders have sold 50,277 shares of company stock valued at $28,513,384. 0.32% of the stock is owned by insiders.

Thermo Fisher Scientific Stock Up 0.3 %

Thermo Fisher Scientific stock traded up $1.87 during midday trading on Friday, reaching $573.60. The stock had a trading volume of 1,438,184 shares, compared to its average volume of 1,317,052. The firm’s fifty day simple moving average is $573.60 and its 200-day simple moving average is $529.90. Thermo Fisher Scientific Inc. has a 1-year low of $415.60 and a 1-year high of $603.82. The stock has a market capitalization of $218.95 billion, a P/E ratio of 36.79, a price-to-earnings-growth ratio of 2.41 and a beta of 0.80. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.39 and a current ratio of 1.70.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share for the quarter, topping the consensus estimate of $4.70 by $0.41. The firm had revenue of $10.35 billion for the quarter, compared to analyst estimates of $10.14 billion. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. As a group, analysts expect that Thermo Fisher Scientific Inc. will post 21.54 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, April 15th. Shareholders of record on Friday, March 15th were given a dividend of $0.39 per share. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. The ex-dividend date was Thursday, March 14th. This represents a $1.56 annualized dividend and a dividend yield of 0.27%. Thermo Fisher Scientific’s payout ratio is 10.01%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.